 Insider Monkey (blog) | Biogen Idec Inc. (BIIB): What Goes up Must Come Down Insider Monkey (blog) On April 4, the company announced positive results from the phase 2 study of daclizumab HYP, another drug for MS which Biogen is developing in partnership with AbbVie Inc (NYSE:ABBV). Earlier, in March, the company submitted a Biologics License ... |
